Advertisement

International Journal of Clinical Pharmacy

, Volume 33, Issue 2, pp 221–228 | Cite as

Dose standardisation of anticancer drugs

  • Anne-Lise Pouliquen
  • Laurence Escalup
  • Nathalie Jourdan
  • Paul Cottu
  • Pierre Faure
  • Isabelle Madelaine-Chambrin
Research Article

Abstract

Objective of the study Body size based dosing is often used for prescribing anticancer drugs. However the scientific and the clinical rationales of this historical method have recently been criticized. As a result, alternative dosing strategies have been suggested, as flat-fixed dosing regimens, but not implemented in routine practice. Dose standardisation is a first step in order to rationalise chemotherapy dose calculation. A new method, derived from dose-banding, was developed, taking into account prescription and economic criteria. Setting Feasibility and interest of this concept were studied in two French cancer centres Institut Curie and Hôpital Saint-Louis. Main outcome measures The aim of our study was to assess dose standardisation of expensive anticancer drugs in objectives of quality and economy. Method Nine candidate drugs were selected and standardized rounded doses (SRD) were proposed. To determine the specific standard doses of these two centres, two theoretical and practical methods were applied, and then, their results were compared. For each anticancer drug the objective was to fix SRD in order to cover all the doses most frequently prescribed. Results It has been possible to propose SRD for six of the nine drugs. These SRD have been implemented with the agreement of the medical staff. These doses are, whenever possible, rounded to the nearest vial size, or correspond to a combination of the different strength of the commercial drug. Conclusion Our study shows that dose standardisation is a help to optimise the productivity and improve the organisation of the preparation unit.

Keywords

Anticancer drugs Dose-banding Dose calculation Standardisation Standardized rounded doses 

Notes

Acknowledgments

The authors would like to thank Dr Sandy Blondeel and Sylvie Carrie for their contribution.

Funding

None.

Conflicts of interest

The authors declare no conflicts of interest.

References

  1. 1.
    DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.Google Scholar
  2. 2.
    Pinkel D. Cancer chemotherapy and body surface area. J Clin Oncol. 1998;16:3714–5.PubMedGoogle Scholar
  3. 3.
    Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–44.PubMedGoogle Scholar
  4. 4.
    Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics. 1950;5:783–90.PubMedGoogle Scholar
  5. 5.
    Wang Y, Moss J, Thisted R. Predictors of body surface area. J Clin Anesth. 1992;4:4–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590–611.PubMedGoogle Scholar
  7. 7.
    Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol. 1993;32:411–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Newell DR. Getting the right dose in cancer chemotherapy–time to stop using surface area ? Br J Cancer. 2002;86:1207–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Markman M. ‘Flat-fixed dosing’ of chemotherapy: a concept whose time has come? Curr Oncol Rep. 2005;7:1–2.PubMedCrossRefGoogle Scholar
  10. 10.
    Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82:323–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38:1677–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Gurney H. I don’t underdose my patients, do I? Lancet Oncol. 2005;6:637–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm. 2001;58:1760–4.PubMedGoogle Scholar
  14. 14.
    Loos WJ, de Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol. 2006;24:1499–506.PubMedCrossRefGoogle Scholar
  15. 15.
    Vigneron J. Stability studies of drugs used in oncology: the role of the hospital pharmacist. Eur J Hosp Pharm Pract. 2006;12:75–6.Google Scholar
  16. 16.
    de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract. 2007;13:27–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19:171–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst. 2002;94:1883–8.PubMedGoogle Scholar
  19. 19.
    Leveque D. Use of body weight and body surface area in dosing of anticancer agents in adult patients. Bull Cancer. 2007;94:647–51.PubMedGoogle Scholar
  20. 20.
    Kaestner SA, Sewell GJ. Chemotherapy dosing part II: alternative approaches and future prospects. Clin Oncol (R Coll Radiol). 2007;19:99–107.Google Scholar
  21. 21.
    Baker JP, Jones SE. Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust. J Oncol Pharm Practice. 1998;4:10–4.CrossRefGoogle Scholar
  22. 22.
    Leach RH, Whitmarsh S, Partridge C, Potter SR. New cytotoxics production unit at University hospital, Birmingham. Hosp Pharm. 2000;7:109–10.Google Scholar
  23. 23.
    MacLean F, MacIntyre J, McDade J, Moyes D. Dose banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J. 2003;270:691–3.Google Scholar
  24. 24.
    Leth-Miller D. Dose-banding of gemcitabine. Eur J Hosp Pharm Pract. 2007;2:52.Google Scholar
  25. 25.
    Hirte HW, Kagoma S, Zhong L, et al. Dose banding of chemotherapy doses at the Juravinski Cancer Centre. J Clin Oncol. 2006;24:6099. (abstract).Google Scholar
  26. 26.
    Kaestner S, Sewell G. Dose-banding of carboplatin: rationale and proposed banding scheme. J Oncol Pharm Pract. 2007;13:109–17.PubMedCrossRefGoogle Scholar
  27. 27.
    Kaestner S, Sewell GJ. A National Survey Investigating UK Prescribers’ Opinions on Chemotherapy Dosing and ‘Dose-Banding’. Clin Oncol (R Coll Radiol). 2009;21:320–8.Google Scholar
  28. 28.
    Bonnabry P, Cingria L, Ackermann M, Sadeghipour F, Bigler L, Mach N. Use of prospective risk analysis method to improve the safety of the cancer chemotherapy process. Int J Qual Health Care. 2005;18:9–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Chen CS, Seidel K, Armitage JO, et al. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997;3:331–40.PubMedGoogle Scholar
  30. 30.
    Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Kaestner S, Sewell G. Pharmacoeconomic aspects of dose-banding. Hosp Pharm Eur. 2006;26:33–4.Google Scholar
  32. 32.
    Kaestner S, Walker V, Roberts S, Perren T, Sewell G. Clinical and pharmacokinetic (pk) study on “dose-banded” and individual-dose chemotherapy: An interim report. J Oncol Pharm Practice. 2004;10:100.Google Scholar
  33. 33.
    Gillian A. British Oncology Pharmacy Association: www.bopawebsite.org. Toolkit: How to implement dose banding of chemotherapy. Accessed on 08/09/2008.

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Anne-Lise Pouliquen
    • 1
  • Laurence Escalup
    • 2
  • Nathalie Jourdan
    • 1
  • Paul Cottu
    • 3
  • Pierre Faure
    • 1
  • Isabelle Madelaine-Chambrin
    • 1
  1. 1.Pharmacy DepartmentHôpital Saint-LouisParisFrance
  2. 2.Pharmacy DepartmentInstitut CurieParisFrance
  3. 3.Oncology DepartmentInstitut CurieParisFrance

Personalised recommendations